You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 323 Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients

Article Text

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
323 Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients

https://doi.org/10.1136/jitc-2020-SITC2020.0323

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.